NCT00956397

Does Small Intestinal Bacterial Overgrowth Contribute to Functional Dyspepsia

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 55 (actual)
• Sponsor: Henry C. Lin, MD · Federal
• Sex: All
• Age: 21 Years
• Healthy volunteers: Accepted

Summary

The prevalence of functional dyspepsia (FD) is estimated to be 15% of the adult population. FD is commonly described as a condition of chronic abdominal discomfort localized to the upper abdomen. Postprandial bloating, pain, nausea, vomiting, belching, and early satiety are common symptoms of the FD patient. FD is defined by \>12 weeks of symptoms, which need not be consecutive, within the preceding year consisting of a) persistent or recurrent dyspepsia and b) an absence of organic disease after a gastrointestinal endoscopy or x-ray series. FD is therefore considered a disorder of function because no mucosal pathology is seen in these patients, as in patients with other functional disorders such as irritable bowel syndrome (IBS) and fibromyalgia (FM). There is a remarkable degree of overlap among these three disorders. These 3 disorders share the finding of hypersensitivity and the symptom of postprandial bloating to suggest the possibility of a common origin.

Conditions

• Functional Dyspepsia
• Small Intestinal Bacterial Overgrowth
• Chronic Abdominal Discomfort

Interventions

Type	Name	Description
DRUG	Rifaximin	rifaximin 550 mg TID PO x 10 days
PROCEDURE	Lactulose Breath Test	Test will begin with a baseline breath sample followed by ingestion of 10g of lactulose (Xactdose, South Beloit, IL) in 100ml of water. Breath samples will be collected every 15 min for 180 min. Gas samples will be analyzed for hydrogen and methane using a gas chromatograph (Model SC, Quintron Instruments, Milwaukee, WI).
DRUG	Placebo	placebo TID x 10 days

Timeline

• Start date: 2007-08-01
• Primary completion: 2012-03-01
• First posted: 2009-08-11
• Last updated: 2012-10-24

Locations

1 site across 1 country: United States